CD274 and Sjogren syndrome: showed that in a sample of 908 patients, the estimated prevalence of Sjögren’s syndrome as an immune-related adverse event in patients treated with anti-PD1/anti-PD-L1 agents alone or in combination with anti-PD1 and anti-CTLA-4 agents was 0.3% and 2.5%, respectively (3).